Verastem, Inc., a biopharmaceutical company, focuses on discovering and developing proprietary small molecule drugs targeting cancer stem cells (CSCs) with companion diagnostics. Its programs target the Focal Adhesion Kinase (FAK) and the PI3K/mTOR signaling pathways. The companys lead FAK inhibitor, VS-6063, is in Phase I/Ib testing in ovarian cancer, as well as developing for the treatment of mesothelioma and breast cancer. It is also developing FAK inhibitor VS-4718 and PI3K/mTOR inhibitor VS-5584 in patients with advanced cancers. The companys product candidates target CSCs that have been implicated in aggressive cancers, metastasis, and chemotherapeutic resistance. Verastem, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
May 27, 2023
RegMed Investors (RMi) Research Note: Q1/23 earnings reporting dates, net losses, cash positions and runway outcomes
May 16, 2023
RegMed Investors’ (RMi) closing bell: biotech, cell and gene therapy sector sinks
May 16, 2023
RegMed Investors’ (RMi) pre-open: are we owning the unownable?
May 15, 2023
RegMed Investors’ (RMi) closing bell: a waiting game
May 12, 2023
RegMed Investors’ (RMi) closing bell: sector sentiment and conviction dampened by economic/inflation headwinds
May 11, 2023
RegMed Investors’ (RMi) closing bell: under pressure with share pricing deceleration
May 10, 2023
RegMed Investors’ (RMi) closing bell: economic expectation influences share pricing reality
May 5, 2023
RegMed Investors’ (RMi) closing bell: sentiment is overstretched yet, a solid Friday upside response
35 companies, 1 interpreter!
Insight, foresight and recommendation
Verastem (VSTM) -- Opened 2018 at $3.21, started February at $3.55 and March at $3.05 with a high of $3.24 on 3/6 - neeeds news which always stimulates volume and pricing offsetting complacency in share pricing ...
holdMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors